A Look At Recursion Pharmaceuticals (RXRX) Valuation As AI Drug Discovery Progress And Earnings Expectations Gain Attention

Recursion Pharmaceuticals (RXRX) is back in focus after management detailed AI driven gains in drug discovery, including 25 new targets identified at once, as investors look ahead to an earnings ...
Nasdaq

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results

SALT LAKE CITY, Feb. 28, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and ...
The Motley Fool

Is Recursion Pharmaceuticals Stock a Buy?

Recursion Pharmaceuticals wants to disrupt drug development. It's leaning on new information technology and automation methods. For the moment, it lacks any big wins to point to. Still, innovative ...
Seeking Alpha

Recursion Announces Phase 2 Data of REC-994, a First-in-Disease Investigational Treatment for Symptomatic Cerebral Cavernous Malformation (CCM), has Met its Primary Endpoint of ...

SALT LAKE CITY, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced top-line results of ...
Seeking Alpha

Recursion Provides Business Updates and Reports Third Quarter 2024 Financial Results

SALT LAKE CITY, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today reported business updates ...